Eric Yvon

5.3k citations

49 papers · 3.6k indexed · 1 hit paper · h-index 28

Oncology top 1%
- CAR-T cell therapy research 27
Immunology top 1%
- Immune Cell Function and Interaction 24
- T-cell and B-cell Immunology 11
- Immunotherapy and Immune Responses 9
- Immunodeficiency and Autoimmune Disorders 4
Genetics top 2%
- Virus-based gene therapy research 8
- Chronic Lymphocytic Leukemia Research 6
Genetics top 5%
- Virus-based gene therapy research 8
- Chronic Lymphocytic Leukemia Research 6
Hematology top 5%
- Hematopoietic Stem Cell Transplantation 4

Co-authors: Malcolm K. Brenner Gianpietro Dotti Helen E. Heslop Cliona M. Rooney Barbara SavoldoHao LiuMartin Pulé Ettore Biagi
Cited by: Oncology Immunology Genetics
Journals: Blood (12 papers)Cytotherapy (9 papers)Clinical Cancer Research (5 papers)
Partner nations: United States Italy France

In The Last Decade

Eric Yvon

47 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Eric Yvon

Since Specialization

Citations

This map shows the geographic impact of Eric Yvon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Yvon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Yvon more than expected).

Fields of papers citing papers by Eric Yvon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Yvon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Yvon. The network helps show where Eric Yvon may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Eric Yvon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eric Yvon Line = papers co-authored together Eric Yvon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β Molecular Therapy — Methods & Clinical Development ·甲寅日刊社,Oswaldo Murillo Ramírez,Ehsan Dowlati,Haili Lang,Sabrina Perissutti,Eugene Hwang,Christopher A. Lazarski,Eric Yvon,Matthias Holdhoff,R. Brad Jones,Barbara Savoldo,Carolina Colli Cruz,Catherine M. Bollard	2022	28
2	CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma Nano Research ·Preethi B. Balakrishnan,A L Cerullo,Juliana Cano‐Mejia,Jaclyn Andricovich,Erica Palmer,Vishal Patel,Patricia S. Latham,Eric Yvon,О. М. Кошовий,Rohan Fernandes,Elizabeth E. Sweeney	2021	28
3	Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma Clinical Cancer Research ·Rachel A. Burga,Eric Yvon,Elizabeth Chorvinsky,Rohan Fernandes,Carolina Colli Cruz,Catherine M. Bollard	2019	69
4	Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma Cytotherapy ·Eric Yvon,Rachel A. Burga,Allison B. Powell,Carolina Colli Cruz,Rohan Fernandes,Cecilia Barese,Nguyễn Tường Vân,Mohamed S Abdelbaki,Catherine M. Bollard	2017	108
5	Gene Modification of Human Natural Killer Cells Using a Retroviral Vector Methods in molecular biology ·Joshua Kellner,Carolina Colli Cruz,Catherine M. Bollard,Eric Yvon	2016	7
6	All-in-one processing of heterogeneous human cell grafts for gene and cell therapy Molecular Therapy — Methods & Clinical Development ·Ekaterina Y. Lukianova‐Hleb,Eric Yvon,Elizabeth J. Shpall,Dmitri O. Lapotko	2016	5
7	Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells Cytotherapy ·Rachel A. Burga,Nguyễn Tường Vân,Joshua Neveu,Richard Low,Loyda Ylisastigui,Rohan Fernandes,Eric Yvon	2016	25
8	Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity Clinical Cancer Research ·Alana A. Kennedy‐Nasser,Stephanie Ku,Isom Nasriyah,Yasmin Hazrat,Meng-Fen Wu,Hao Liu,Jos Melenhorst,A. John Barrett,Sawa Ito,Aaron E. Foster,Barbara Savoldo,Eric Yvon,George Carrum,Carlos A. Ramos,Robert A. Krance,Kathryn Leung,Helen E. Heslop,Malcolm K. Brenner,Catherine M. Bollard	2014	145
9	Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking Cell Death and Differentiation ·Beatriz Martín-Antonio,Aigi Vitsin,Simon N. Robinson,Claude Chew,Alice Stocco,Eric Yvon,Jian-Yan Pan,Hongda YU,Robert Z. Orlowski,Cristina Muñoz‐Pinedo,Clara Bueno,Pablo Menéndez,Carlos Fernández de Larrea,Álvaro Urbano-Ispizúa,Elizabeth J. Shpall,Nirav R. Shah	2014	16
10	T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo Clinical Cancer Research ·Claudia Geldres,Barbara Savoldo,Valentina Hoyos,Ignazio Caruana,Ming Zhang,Eric Yvon,Michele Del Vecchio,Chad J. Creighton,Michael Ittmann,Soldano Ferrone,Gianpietro Dotti	2013	80
11	Third-party umbilical cord blood–derived regulatory T cells prevent xenogenic graft-versus-host disease Cytotherapy ·Simrit Parmar,Xiaoying Liu,Michelle M. Staryos,Simon N. Robinson,Gabriel Rodriguez,Laurence J.N. Cooper,Hui Yang,Nina Shah,Hong Yang,Marina Konopleva,А. Гусейин,Guillermo Garcia‐Manero,Amer Najjar,Eric Yvon,Ian McNiece,Katy Rezvani,Barbara Savoldo,Catherine M. Bollard,Elizabeth J. Shpall	2013	45
12	Combining mTor Inhibitors With Rapamycin-resistant T Cells: A Two-pronged Approach to Tumor Elimination Molecular Therapy ·Leslie E. Huye,Yozo Nakazawa,Mayuri Patel,Eric Yvon,Jiali Sun,Barbara Savoldo,Matthew H. Wilson,Gianpietro Dotti,Cliona M. Rooney	2011	39
13	Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells Clinical Cancer Research ·Eric Yvon,Michele Del Vecchio,Barbara Savoldo,Valentina Hoyos,Aurélie Dutour,Andrea Anichini,Gianpietro Dotti,Malcolm K. Brenner	2009	113
14	Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression Molecular Therapy ·Nabil Ahmed,Vita S. Salsman,Eric Yvon,Chrystal U. Louis,László Perlaky,Winfried S. Wels,J.H. Kwantes,Eugenie E Kleinerman,Martin Pulé,Cliona M. Rooney,Helen E. Heslop,Stephen Gottschalk	2009	167
15	Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression Molecular Cancer ·Aaron E. Foster,Fatma Visal Okur,Ettore Biagi,An Lu,Gianpietro Dotti,Eric Yvon,Barbara Savoldo,George Carrum,Michael Andreeff,Margaret A. Goodell,Helen E. Heslop,Malcolm K. Brenner	2009	4
16	Exploiting Cytokine Secretion to Rapidly Produce Multivirus-specific T Cells for Adoptive Immunotherapy Journal of Immunotherapy ·Yuriko Fujita,Ann M. Leen,Jiali Sun,Yozo Nakazawa,Eric Yvon,Helen E. Heslop,Malcolm K. Brenner,Cliona M. Rooney	2008	35
17	Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells Cancer Gene Therapy ·Leanne Mielczarek,E. Biagi,Cornell Allen,Rama Shivakumar,Jonathan M. Weiss,A. R. Egypt,Eric Yvon,Joseph C. Fratantoni,A. Cavallaro	2005	18
18	Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells Blood ·Eric Yvon,Stéphane Vigouroux,Raphaël F. Rousseau,Ettore Biagi,Persis Amrolia,Gianpietro Dotti,Hans-Joachim Wagner,Malcolm K. Brenner	2003	128
19	Cancer vaccines: dream, reality, or nightmare? Clinical and Experimental Medicine ·E. Biagi,Raphaël F. Rousseau,Eric Yvon,S. Vigouroux,Gianpietro Dotti,Malcolm K. Brenner	2002	4
20	Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma International Journal of Cancer ·B. Gahn,Fernando Siller-López,Tingtimg Huang,Eric Yvon,Stephen Gottschalk,Richard Longnecker,Malcolm K. Brenner,Helen E. Heslop,Estuardo Aguilar-Córdova,Cliona M. Rooney	2001	65

About Eric Yvon

Eric Yvon is a scholar working on Immunology, Oncology, Genetics, Hematology and Biotechnology, having authored 49 papers that have together received 3.6k indexed citations. Recurring topics across this work include CAR-T cell therapy research (27 papers), Immune Cell Function and Interaction (24 papers), T-cell and B-cell Immunology (11 papers), Immunotherapy and Immune Responses (9 papers), Virus-based gene therapy research (8 papers), Chronic Lymphocytic Leukemia Research (6 papers), Immunodeficiency and Autoimmune Disorders (4 papers) and Hematopoietic Stem Cell Transplantation (4 papers). The work is most often cited by research in Oncology (2.6k citations), Immunology (1.8k citations), Genetics (867 citations), Genetics (206 citations) and Hematology (210 citations). Eric Yvon has collaborated with scholars based in United States, Italy and France. Frequent co-authors include Malcolm K. Brenner, Gianpietro Dotti, Helen E. Heslop, Cliona M. Rooney, Barbara Savoldo, Hao Liu, Martin Pulé, Ettore Biagi, Chrystal U. Louis and Stéphane Vigouroux. Their work appears in journals such as Blood, Cytotherapy, Clinical Cancer Research, Molecular Therapy and Molecular Therapy — Methods & Clinical Development.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact